Figure 2: 30-Day Mortality and Composite of Death, Shock, or CHF by Treatment With Pexelizumab Versus Placebo (APEX-AMI, Phase 3)

2019-06-11T07:04:26Z (GMT) by Jennifer A. Rymer L. Kristin Newby
(A) 30-day mortality; (B) composite of death, shock, or CHF. APEX AMI = Assessment of Pexelizumab in Acute Myocardial Infarction; CHF = congestive heart failure; CI = confidence interval; HR = hazard ratio.



Elsevier user license